Here’s what you should know:
1. Dr. Kelley previously served as the company’s vice president of medical affairs.
2. In this new position, Dr. Kelley will assume responsibility for all of Flexion Therapeutics’ medical matters.
3. Before joining Flexion in May 2016, Dr. Kelley was Sanofi’s vice president of global medical affairs. At Sanofi, he oversaw global data generation, data dissemination and served as a key opinion leader.
Flexion CEO Michael Clayman, MD, said, “Scott has demonstrated a singular combination of rigor and creativity with respect to clinical trial design, clinical data analysis and the consideration of pipeline candidates, and he melds those skills with an innate ability to communicate ideas and data with passion and clarity. … We look forward to his continued success in his expanded role at this critical juncture in the company’s evolution.”
More articles on anesthesia:
Ancillary procedure payments cut under 2018 CMS Physician Fee Schedule — 5 insights
New Jersey Monthly names NAPA partner Dr. Jonathan Markley a top doctor — 4 insights
Anesthesia Business Consultants attends 71st Annual PostGraduate Assembly in Anesthesiology — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.